Skip to content

Study · Randomized controlled trial · n = 80 · 2013

12 results

Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.

Matyjaszek-Matuszek B, Lenart-Lipińska M, Rogalska D, Nowakowski A

Endokrynologia Polska1 Jan 2013Cited by 2 (Europe PMC)

PMID24186595 (opens in a new tab)DOI10.5603/ep.2013.0021 (opens in a new tab)PepBankPUB-24186595
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Polish patients with diabetes, post-breakfast glucose excursions were smaller with exenatide than insulin glargine.

    In plain wordsIn Polish patients with diabetes, glucose rose less after breakfast with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePost-breakfast glucose excursion
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Postprandial glucose excursions after breakfast and dinner were smaller in patients treated with exenatide.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Polish patients with diabetes, post-dinner glucose excursions were smaller with exenatide than insulin glargine.

    In plain wordsIn Polish patients with diabetes, glucose rose less after dinner with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePost-dinner glucose excursion
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Postprandial glucose excursions after breakfast and dinner were smaller in patients treated with exenatide.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Polish patients with diabetes, exenatide reduced body weight versus insulin glargine, with a between-group difference of -3.5 kg.

    In plain wordsIn Polish patients with diabetes, weight fell with exenatide but rose with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −1.9 kg
    exenatide
    Body weight change
    1.6 kg
    insulin glargine
    Between-group weight difference
    −3.5 kg
    exenatide versus glargine

    Source sentences

    Summary
    LS mean (SEM) body weight decreased by -1.9 (0.48) kg with exenatide and increased by 1.6 (0.48) kg with glargine (group difference [95%CI]: -3.5 kg [-4.9 to -2.2]).
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  4. 04HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, hypoglycemia was low with both exenatide and insulin glargine.

    In plain wordsIn Polish patients with diabetes, low blood sugar was uncommon with both exenatide and insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedHypoglycemia
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemia was low in both groups
  5. 05HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, nocturnal hypoglycemia affected three exenatide patients versus seven insulin glargine patients.

    In plain wordsIn Polish patients with diabetes, fewer exenatide patients had nighttime low blood sugar than insulin glargine patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNocturnal hypoglycemia patients
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Patients with nocturnal hypoglycaemia
    3 patients
    exenatide
    Patients with nocturnal hypoglycaemia
    7 patients
    insulin glargine

    Source sentences

    Summary
    Hypoglycaemia was low in both groups; nocturnal hypoglycaemia was reported for three v. seven patients (three v. 24 episodes) in the exenatide and glargine groups, respectively.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  6. 06HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, nocturnal hypoglycemia comprised three episodes with exenatide versus 24 with insulin glargine.

    In plain wordsIn Polish patients with diabetes, nighttime low blood sugar episodes were fewer with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNocturnal hypoglycemia episodes
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Nocturnal hypoglycaemia episodes
    3 episodes
    exenatide
    Nocturnal hypoglycaemia episodes
    24 episodes
    insulin glargine

    Source sentences

    Summary
    Hypoglycaemia was low in both groups; nocturnal hypoglycaemia was reported for three v. seven patients (three v. 24 episodes) in the exenatide and glargine groups, respectively.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  7. 07HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, adverse events were more common with exenatide than insulin glargine.

    In plain wordsIn Polish patients with diabetes, adverse events were more common with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdverse events
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Whole body
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  8. 08HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, nausea affected 22 exenatide patients versus 1 insulin glargine patient.

    In plain wordsIn Polish patients with diabetes, nausea affected more exenatide patients than insulin glargine patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Nausea
    22 patients
    exenatide
    Nausea
    1 patients
    insulin glargine

    Source sentences

    Summary
    Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  9. 09HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, vomiting affected 5 exenatide patients versus 0 insulin glargine patients.

    In plain wordsIn Polish patients with diabetes, vomiting affected more exenatide patients than insulin glargine patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseVomiting
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Vomiting
    5 patients
    exenatide
    Vomiting
    0 patients
    insulin glargine

    Source sentences

    Summary
    Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).
  10. 10HumanRandomized controlled trialSafety outcome

    In Polish patients with diabetes, headache affected 8 exenatide patients versus 2 insulin glargine patients.

    In plain wordsIn Polish patients with diabetes, headache affected more exenatide patients than insulin glargine patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHeadache
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    10 μg BID · 26 weeksAs given in this study (human).

    Measurements

    Patients with headache
    8 patients
    exenatide BID
    Patients with headache
    2 patients
    insulin glargine

    Source sentences

    Summary
    Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In Polish patients with diabetes, HbA1c fell by 0.72% with exenatide and 0.64% with insulin glargine.

    In plain wordsIn Polish patients with diabetes, HbA1c fell with both exenatide and insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −0.72%
    exenatide
    HbA1c change
    −0.64%
    insulin glargine

    Source sentences

    Summary
    At Week 26, LS mean (SEM) HbA1c decreased in both groups (exenatide -0.72% [0.12]; glargine -0.64% [0.12]), as did fasting glucose.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In Polish patients with diabetes, fasting glucose decreased with both exenatide and insulin glargine.

    In plain wordsIn Polish patients with diabetes, fasting glucose decreased with both exenatide and insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting glucose
    Study

    n = 80

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At Week 26, LS mean (SEM) HbA1c decreased in both groups (exenatide -0.72% [0.12]; glargine -0.64% [0.12]), as did fasting glucose.
    3 context sentences
    Summary · context
    We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.
    Summary · context
    In Poland, 80 patients (HbA1c 7-10%, BMI 25-45 kg/m(2)) were randomised to exenatide 10 μg BID (n = 40) or insulin glargine once daily (n = 40).
    Summary · context
    We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.